Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy

Yepeng Luan, Jerry Li, Jean A. Bernatchez, Rongshi Li

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Histone deacetylases (HDACs), encompassing at least 18 members, are promising targets for anticancer drug discovery and development. To date, five histone deacetylase inhibitors (HDACis) have been approved for cancer treatment, and numerous others are undergoing clinical trials. It has been well validated that an agent that can simultaneously and effectively inhibit two or more targets may offer greater therapeutic benefits over single-acting agents in preventing resistance to treatment and in potentiating synergistic effects. A prime example of a bifunctional agent is the hybrid HDAC inhibitor. In this perspective, the authors review the majority of reported kinase/HDAC hybrid inhibitors.

Original languageEnglish (US)
Pages (from-to)3171-3183
Number of pages13
JournalJournal of Medicinal Chemistry
Volume62
Issue number7
DOIs
StatePublished - Apr 11 2019

Fingerprint

Histone Deacetylase Inhibitors
Histone Deacetylases
Phosphotransferases
Neoplasms
Drug Discovery
Therapeutics
Clinical Trials

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy. / Luan, Yepeng; Li, Jerry; Bernatchez, Jean A.; Li, Rongshi.

In: Journal of Medicinal Chemistry, Vol. 62, No. 7, 11.04.2019, p. 3171-3183.

Research output: Contribution to journalArticle

Luan, Yepeng ; Li, Jerry ; Bernatchez, Jean A. ; Li, Rongshi. / Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy. In: Journal of Medicinal Chemistry. 2019 ; Vol. 62, No. 7. pp. 3171-3183.
@article{2707750b3c744441bd810950a95994df,
title = "Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy",
abstract = "Histone deacetylases (HDACs), encompassing at least 18 members, are promising targets for anticancer drug discovery and development. To date, five histone deacetylase inhibitors (HDACis) have been approved for cancer treatment, and numerous others are undergoing clinical trials. It has been well validated that an agent that can simultaneously and effectively inhibit two or more targets may offer greater therapeutic benefits over single-acting agents in preventing resistance to treatment and in potentiating synergistic effects. A prime example of a bifunctional agent is the hybrid HDAC inhibitor. In this perspective, the authors review the majority of reported kinase/HDAC hybrid inhibitors.",
author = "Yepeng Luan and Jerry Li and Bernatchez, {Jean A.} and Rongshi Li",
year = "2019",
month = "4",
day = "11",
doi = "10.1021/acs.jmedchem.8b00189",
language = "English (US)",
volume = "62",
pages = "3171--3183",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy

AU - Luan, Yepeng

AU - Li, Jerry

AU - Bernatchez, Jean A.

AU - Li, Rongshi

PY - 2019/4/11

Y1 - 2019/4/11

N2 - Histone deacetylases (HDACs), encompassing at least 18 members, are promising targets for anticancer drug discovery and development. To date, five histone deacetylase inhibitors (HDACis) have been approved for cancer treatment, and numerous others are undergoing clinical trials. It has been well validated that an agent that can simultaneously and effectively inhibit two or more targets may offer greater therapeutic benefits over single-acting agents in preventing resistance to treatment and in potentiating synergistic effects. A prime example of a bifunctional agent is the hybrid HDAC inhibitor. In this perspective, the authors review the majority of reported kinase/HDAC hybrid inhibitors.

AB - Histone deacetylases (HDACs), encompassing at least 18 members, are promising targets for anticancer drug discovery and development. To date, five histone deacetylase inhibitors (HDACis) have been approved for cancer treatment, and numerous others are undergoing clinical trials. It has been well validated that an agent that can simultaneously and effectively inhibit two or more targets may offer greater therapeutic benefits over single-acting agents in preventing resistance to treatment and in potentiating synergistic effects. A prime example of a bifunctional agent is the hybrid HDAC inhibitor. In this perspective, the authors review the majority of reported kinase/HDAC hybrid inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85057017668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057017668&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.8b00189

DO - 10.1021/acs.jmedchem.8b00189

M3 - Article

C2 - 30418766

AN - SCOPUS:85057017668

VL - 62

SP - 3171

EP - 3183

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 7

ER -